Skip to main content
Search
Australia’s active vaccine safety system
Search
Secondary Menu
Contact
About us
Our purpose
Funding and governance
Our history
Our people
Our collaborators
FAQs
Our work
National vaccine safety surveillance
Active vaccine safety surveillance
COVID-19 vaccine safety surveillance
Adverse event of special interest (AESI) long-term follow-up program
Adverse Events Following Immunisation Clinical Assessment Network (AEFI-CAN)
Vaccine safety in Australia AusVaxSafety summary report
Publications
Vaccine safety data
COVID-19 vaccines
Influenza vaccines
National Immunisation Program schedule vaccines
Mpox (monkeypox) vaccine
Shingrix®
News & events
Resources
Contact
Main navigation
About us
Our purpose
Funding and governance
Our history
Our people
Our collaborators
FAQs
Our work
National vaccine safety surveillance
Active vaccine safety surveillance
COVID-19 vaccine safety surveillance
Adverse event of special interest (AESI) long-term follow-up program
Adverse Events Following Immunisation Clinical Assessment Network (AEFI-CAN)
Vaccine safety in Australia AusVaxSafety summary report
Publications
Vaccine safety data
COVID-19 vaccines
Influenza vaccines
National Immunisation Program schedule vaccines
Mpox (monkeypox) vaccine
Shingrix®
News & events
Resources
News & events
28 March 2024
| News
AusVaxSafety commences routine surveillance of 2024 seasonal influenza vaccines
08 March 2024
| News
Vaccine safety in Australia AusVaxSafety summary report now available
20 February 2024
| News
What to expect in the days after your XBB.1.5 COVID-19 vaccine
20 December 2023
| News
Shingrix® vaccine safety data now available
28 November 2023
| News
AusVaxSafety monitoring monovalent Omicron XBB.1.5 variant COVID-19 vaccine safety
07 November 2023
| News
AusVaxSafety commences enhanced surveillance of Shingrix® following addition to the NIP schedule
19 October 2023
| News
AusVaxSafety surveillance of 2023 seasonal flu vaccines concludes with no safety issues identified
14 September 2023
| News
Vaxtracker wins Hunter New England Health Excellence Award
17 May 2023
| News
Subcutaneous and intradermal administration of mpox vaccine well tolerated, AusVaxSafety study finds
10 May 2023
| News
New bivalent BA.4/BA.5 COVID-19 booster vaccines well tolerated by Australians, new AusVaxSafety data show
All news & events
Tue, 01/17/2017
| News
The backstory to a landmark development for vaccine safety
Access the full Croakey article here.
Share this article: